Thinking outside the laboratory : analyses of antibody structure and dynamics within different solvent environments in molecular dynamics (MD) simulations by Al Qaraghuli, Mohammed M. et al.
Al Qaraghuli, Mohammed M. and Kubiak-Ossowska, Karina and 
Mulheran, Paul A. (2018) Thinking outside the laboratory : analyses of 
antibody structure and dynamics within different solvent environments 
in molecular dynamics (MD) simulations. Antibodies, 7 (3). ISSN 2073-
4468 , http://dx.doi.org/10.3390/antib7030021
This version is available at https://strathprints.strath.ac.uk/64628/
Strathprints is  designed  to  allow  users  to  access  the  research  output  of  the  University  of 
Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights 
for the papers on this site are retained by the individual authors and/or other copyright owners. 
Please check the manuscript for details of any other licences that may have been applied. You 
may  not  engage  in  further  distribution  of  the  material  for  any  profitmaking  activities  or  any 
commercial gain. You may freely distribute both the url (https://strathprints.strath.ac.uk/) and the 
content of this paper for research or private study, educational, or not-for-profit purposes without 
prior permission or charge. 
Any correspondence concerning this service should be sent to the Strathprints administrator: 
strathprints@strath.ac.uk
The Strathprints institutional repository (https://strathprints.strath.ac.uk) is a digital archive of University of Strathclyde research 
outputs. It has been developed to disseminate open access research outputs, expose data about those outputs, and enable the 
management and persistent access to Strathclyde's intellectual output.
antibodies
Article
Thinking outside the Laboratory: Analyses of
Antibody Structure and Dynamics within Different
Solvent Environments in Molecular Dynamics
(MD) Simulations
Mohammed M. Al Qaraghuli 1,* ID , Karina Kubiak-Ossowska 1,2 ID and Paul A. Mulheran 1
1 Department of Chemical and Process Engineering, University of Strathclyde, Glasgow G1 1XJ, UK;
karina.kubiak@strath.ac.uk (K.K.-O.); paul.mulheran@strath.ac.uk (P.A.M.)
2 Department of Physics, University of Strathclyde, Glasgow G4 0NG, UK
* Correspondence: mohammed.al-qaraghuli@strath.ac.uk; Tel.: +44-(0)141-548-2176
Received: 2 May 2018; Accepted: 20 June 2018; Published: 24 June 2018


Abstract: Monoclonal antibodies (mAbs) have revolutionized the biomedical field, directly
influencing therapeutics and diagnostics in the biopharmaceutical industry, while continuing
advances in computational efficiency have enabled molecular dynamics (MD) simulations to provide
atomistic insight into the structure and function of mAbs. Despite the success of MD tools, further
optimizations are still required to enhance the computational efficiency of complex mAb simulations.
This issue can be tackled by changing the way the solvent system is modelled to reduce the number
of atoms to be tracked but must be done without compromising the accuracy of the simulations.
In this work, the structure of the IgG2a antibody was analyzed in three solvent systems: explicit
water and ions, implicit water and ions, and implicit water and explicit ions. Root-mean-square
distance (RMSD), root-mean-square fluctuations (RMSF), and interchain angles were used to quantify
structural changes. The explicit system provides the most atomistic detail but is ~6 times slower
in its exploration of configurational space and required ~4 times more computational time on our
supercomputer than the implicit simulations. Overall, the behavior of the implicit and explicit
simulations is quantifiably similar, with the inclusion of explicit ions in the implicit simulation
stabilizing the antibody to reproduce well the statistical fluctuations of the fully explicit system.
Therefore, this approach holds promise to maximize the use of computational resources to explore
antibody behavior.
Keywords: implicit solvent; explicit solvent; root-mean-square distance (RMSD); root-mean-square
fluctuations (RMSF); antibody; molecular dynamics (MD)
1. Introduction
Monoclonal antibody (mAb)-based therapeutics represent a large and growing fraction of all drug
candidates that have emerged to phase 3 clinical trials in 2015 [1]. This dominance is reflected in the
annual number of antibody therapeutics granted a first approval, which has reached double-digits
(total of 10) for the first time in 2017 [2]. The unprecedented interest in these “Y” shaped glycoproteins
has originated from their capability to recognize various antigens or molecular targets with extremely
high affinity. This has enabled the wide adaptation of these antibodies in both diagnostic and
therapeutic applications.
An antibody, as illustrated in Figure 1, generally comprises two heavy and two light polypeptide
chains [3]. Any of the nine characterized heavy-chain subtypes can be linked to either a lambda (λ)
or kappa (k) light chain to create one of the nine antibody subclasses in humans (IgM, IgD, IgG1–4,
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IgA1–2, or IgE) [4]. Since a large proportion of serum immunoglobulins is of the IgG type [5], and most
of the therapeutic antibodies that are licensed or currently in development utilize an IgG backbone [6],
this isotype is studied here.
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Figure 1. Antibody structure.
IgG2a antibody (PDB ID: 1IGT): Four chains (A, B, C, and D) were viewed by VMD [7] in cartoon
format, where barrels, ribbon arrows, and loose strings indicate α-helices, β-sheets, and less structured
parts regions (such as loops), respectively. The heavy chains were coloured as red (B) and orange (D),
whilst the light chains were coloured as blue (A) and grey (C). The IgG antibody can be dissected
into three fragments: two identical antigen-binding fragments (Fabs) that each contain the first two
domains of the heavy (VH and CH1) and light (VL and CL) chains, and one crystallisable region
fragment (Fc) consisting of two monomers, each comprising an N-glycosylated CH2 domain and
a CH3 domain.
Several tools and guidelines have been developed in both academic and commercial settings to
enhance the characterization of antibodies, including structural and physicochemical properties, biological
activity, selectivity and specificity, immunochemical properties, purity, impurities, and contaminants [8,9].
Despite the robustness of the developed approaches, the recent computational revolution has undoubtedly
added an extra edge to the discovery and development of these bio-therapeutics. Computer-aided drug
design (CADD) is being utilized to accelerate in silico hit identification, hit-to-lead selection, structural
analysis, optimization of the pharmacokinetic/ pharmacodynamics profile, and to anticipate binding
and safety issues [10]. The diversified range of CADD applications has even spanned most stages of
target identification, lead discovery, and expanded to preclinical or clinical trials [11,12].
Molecular dynamics (MD) simulations have been proposed as a predictive tool that can provide
comprehensive atomistic insight into the complex structure of proteins and, in particular, antibodies.
MD simulations have successfully provided information about interactions, flexibility, interfacial
dynamics and electrostatics analysis, and binding of small and macrobiomolecules or DNA to
nanoparticles [13–15]. Moreover, MD simulations were effectively used to analyze antibody–antigen
interactions [16], antibody fragment conformational stability [17], thermal stress and deglycosylation
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impact on the antibody conformational stability [18], and to investigate the role of individual
amino acids on the internal dynamics of antibodies [19]. Subsequently, MD simulations provide
a prospective analysis that can guide a specific and site-directed optimization and engineering of
new bio-therapeutics.
Despite the aforementioned successes, MD simulations place significant limitations on the
time and length scales that can be investigated. In general, MD simulations are performed by
considering the solvent molecules explicitly, computing all interactions between the solute and solvent
atoms. The fully explicit system can be considered as the most accurate and detailed approach
for biomolecular simulations. However, the inclusion of explicit solvent molecules substantially
reduces the computational efficiency [20]. Since computational cost and access to supercomputers
can limit the uptake of these simulations, many strategies to facilitate efficient sampling of the
protein configurational space have been developed, including coarse-grained modelling [21], adaptive
biased dynamics [22], and implicit solvation [23]. Implicit solvation can accelerate simulations by
approximating the discrete solvent as a continuum using the generalized Born (GB) model [23].
Such an approach considerably decreases the number of particles tracked in the system and leads to
faster sampling of the conformational space, which is mainly due to the reduced effective viscosity
of the solvent introduced by this approximate method [24]. Conformational sampling in implicit
solvent simulations can be, for instance, ~100 times faster compared to common explicit solvent
simulations [25,26].
The accuracy of the implicit-solvent approximations, explicit water models, and the interatomic
force fields has been extensively discussed elsewhere [11,27,28]. However, the effect of two various
solvent environments, explicit versus implicit systems, on the antibody structure and dynamics
has not been studied hitherto. More understanding will undoubtedly guide the biopharmaceutical
industry and antibody-based academic field to select the best simulation options based on the bespoke
requirements of the biomolecules as well as computational resources. Consequently, the focus of this
article will be to analyze the effect of different solvent and ionic environments on the structure of the
analyzed IgG antibody. We have developed a clear understanding of how to analyze different proteins,
like bovine serum albumin and lysozyme [29,30], and our aim here is to translate this knowledge into
the antibody field.
2. Materials and Methods
2.1. Molecular Dynamics Simulations
The simulations were performed with the NAMD 2.11 package [31], using the CHARMM27
force-field, and the results were analyzed using VMD 1.9.1 software [7]. Three sets of simulations were
performed: (i) using explicit water and ions (“explicit” trajectories); (ii) using implicit water and ions
(“implicit”); and (iii) implicit water but explicit ions (“explicit_ions”). The antibody studied is the
IgG2a mouse antibody, and the crystal structure was retrieved from the Protein Data Bank (PDB ID:
1IGT) [32].
In the explicit simulation, the systemwas initially solvated in a cubic water box (TIP3P model) that
extended at least 30 Å from any antibody atom. Then, NaCl salt at ionic strength I = 5 × 10−2 Mwas
added to better reproduce experimental conditions (161 Na+ and 161 Cl− ions were used in this case).
The simulation system shown in Figure 2A was composed of 537,646 atoms in total (antibody: 20,148;
water: 517,176; ions: 322), and the size of the obtained simulation box was 147 Å × 197 Å × 196 Å.
The simulation was conducted through three stages: (i) water and ion minimization (1000 steps)
and subsequent 100 ps run (integration step of 1 fs) in constant temperature of 300 K (trajectory D0);
(ii) minimization of the entire system (10,000 steps) followed by 60 ps heating to 300 K and equilibration
(integration step of 2 fs) at constant temperature for 5.94 ns (trajectory D1); and (iii) the production
trajectory (D2) of 100 ns duration with a 2 fs time step. The antibody atoms were immobilized only
during the initial minimization stage. The simulation was performed in the NVT ensemble with
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a Langevin thermostat as implemented in NAMD [31]. The cutoff for VdW interactions was 12 Å,
while the PME method was used for electrostatics [33]. In total, we had six independent trajectories,
each under different conditions, that showed similar general behavior, and here, analyzed in detail,
is one with the single antibody in its water box.ȱŘŖŗŞǰȱŝǰȱ¡ȱȱȱ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Figure 2. Antibody electrostatic potential and representation in primary simulation cell. (A) The
explicit solvent (and ions) model illustrated by VMD [7]. The antibody is shown as a surface model;
heavy chains are indicated in blue, while light chains are in red. Ions are shown by spheres: Cl− in
yellow and Na+ in cyan. The box is filled by water shown as transparent lines for clarity; (B) The
surface-mapped electrostatic energy of IgG2a was calculated and viewed by Python Molecule Viewer
(PMV) v. 1.5.6 [34]. The map colour was coded as white: 0 kT/e, Blue: 9.98 kT/e, Red: −9.98 kT/e.
Water, as a dielectric medium, screens (or reduces) the electrostatic interactions between charged
species, therefore, in the implicit method, it is modelled as a dielectric continuum. The GB
approximation models ions as charged spheres, the internal dielectric constant of which is lower
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than that of the solvent. The screening that each charged atom experiences is, therefore, determined
by its local environment; the more an atom is surrounded by other atoms, the less its electrostatic
field is screened by the solvent. The GB method reduces the computational costs of the simulations,
since fewer atomic positions are explicitly computed on each time step, although the computations
are more involved using the GB electrostatic model. Hence, less computational time is required
to calculate a given trajectory length and, simultaneously, the conformational space sampling is
accelerated, while the speedup factor strongly depends on the system studied [24]. This makes the GB
method very attractive when long-time simulations are required for relatively large systems. On the
other hand, the quality of these trajectories needs to be examined carefully, since the lowered barriers
in the implicit solvent models might lead and trap the system in irrelevant energy basins.
The implicit-water simulation protocol was kept as close to the above as possible. The GB implicit
solvent model, as implemented in NAMD [31], was used with α cutoff 12 Å and ion concentration
5 × 10−2 M, modifying the default settings of the water medium. In all stages, the electrostatic and
vdW cutoff was 14 Å as recommended in NAMD [31]. It is worth noting that methods using periodic
boundary conditions cannot be combined with this implicit solvent model. The “implicit” production
trajectory was 100 ns duration.
It is instructive to view the electrostatic potential of the antibody surface in the GB implicit model,
since this will help the interpretation of how explicit ions interact with it. The electrostatic potential of
the selected IgG2a antibody was calculated using Adaptive Poisson-Boltzmann Solver (APBS) Version
0.5.1 in the Python Molecule Viewer (PMV) Version 1.5.6 [34] (Compute > Electrostatics > Compute
Potential using APBS). The produced energy was mapped to the surface with medium surface quality
and at a 1 Å distance (Compute > Electrostatics > Map Potential to Surface) and this reproduces well
the electrostatic potential of the protein within the GB model. The electrostatic potential map this
produces is shown in Figure 2B.
The third “explicit_ions” simulation used implicit water solvent while explicitly including Na+
and Cl− ions. Therefore, the ion concentration parameter was set to zero to not double-count the ions.
Na+ and Cl− ions were added at the same locations as found in the explicit simulations. The other
simulation conditions and parameters were as in the previous “implicit” system. We note that, due to
the lack of periodicity in the system, the explicit ions in the implicit solvent model are free to diffuse
away from the protein. Nevertheless, careful initial positioning of the explicit ions (namely, close
to positions the ions would obtain in the explicit simulation) prevents this; the particular charge
distribution on the protein surface is an important factor influencing the explicit ion behavior.
2.2. RMSD, RMSF, and Interchain Angles
Both root-mean-square distance (RMSD) and fluctuations (RMSF) analyses were conducted using
homemade Tcl scripts executed through the Tk Console of VMD [7]. RMSD is a widely used tool in
bioinformatics that quantifies the variability of similar proteins, such as alternative conformations
of the same protein [35]. As used here, this tool measures the degree of the similarity between two
protein three-dimensional (3D) structures with the same number of atoms [36].
The RMSD is defined as
RMSD =
√√√√∑Natomsi=1
∣∣∣→r i(t1)−→r i(t2)
∣∣∣2
Natoms
(1)
where Natoms is the number of atoms in the protein structure and
→
r i(t) is the position of the ith atom
at a given time t. In practice, to calculate the RMSD, the two protein structures to be compared are
initially treated as rigid bodies (no internal flexibility allowed), then overlapped (aligned) using only
translations and rotations.
Another useful tool to track structural changes in proteins is RMSF, where the RMSD is calculated
for each protein residue. It is frequently referred to as “fluctuations” because it reflects each residue’s
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mobility during the MD trajectory. RMSF reports an amplitude of residue movement (fluctuation) from
the average position (in the aligned structures) over the entire length of theMD trajectory. Time average
fluctuations of atoms belonging to the same residue were calculated from the formula
RMSFk =
√√√√
〈
∑
NK
i=1
∣∣∣→r i(t)− 〈→r i〉T
∣∣∣2
NK
〉
T
(2)
where
→
r i(t) is the position of atom i in residue k at time t, Nk is the number of atoms in the residue,
and 〈
→
r i〉T is the time average over the trajectory. Similar to RMSD, an extra component to the RMSF
is introduced if two domains/chains change their relative orientations. To exclude these effects,
we optimized our scripts to focus on each protein fragment. The most frequently used unit for RMSD
and RMSF is Å (10−10 m), which is convenient for the protein length-scale.
The large-scale movement of the Fab and Fc regions was monitored by selecting one amino acid
at the end of these three regions (Fab-right: Lys 65, Fab-left: Asp 31, and Fc: Phe 442) and one amino
acid from the central CH1–CH2 linker region (Cys 225). The angles between the three triplets (left
angle: Asp31_Cys225_Phe442; right angle: Lys65_Cys225_Phe442; top angle: Asp31_Cys225_Lys65)
throughout the simulations were measured using VMD [7].
3. Results and Discussion
General comparison of the total RMSD for the entire antibody in the three solvent environments
reveal an overall stability of the antibody in these simulations (Figure 3). The explicit model shows
lower RMSD values, especially during the first 50 ns (Supplementary Video S1) when compared to the
two implicit models (with or without explicit ions, Supplementary Videos S2 and S3). The second 50 ns
of the simulations show an overall tendency towards steady state behavior, fluctuating around 15–16 Å
and 17–20 Å for the explicit and implicit simulations, respectively. The RMSD value has different
significance and interpretation for long, medium, or short polypeptide chains because it depends on
the number of atoms included in the structural alignment [35]. The RMSD values in Figure 3 can
be considered reasonable for such a large, naturally flexible and complex protein and agrees with
previously reported values for a similar antibody subclass [18] and with a human IgG1 monoclonal
antibody (trastuzumab) [37].
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Figure 3. Total RMSD analysis of the entire antibody. The RMSD of the entire antibody (with all four
chains included) for the three simulations described in the text.
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Despite this general agreement, it is necessary to understand the source of this difference in
RMSD at different stages of each simulation and across the three simulations. Therefore, the RMSD
analyses were extended to each of the four (two heavy and two light) chains of the antibody, as shown
in Figure 4. The four chains show low and approximately similar RMSD in the explicit simulation
(Figure 4A), with the lowest RMSD observed in one of the light chains (chain A). A similar RMSD trend
is observed in the “explicit_ions” simulation, albeit at higher values (Figure 4C). For the “implicit”
simulation, the two heavy chains (D and B) have interchangeably revealed very high RMSD when
compared to the light chains (A and C) of the same simulation and to the other two simulations
(Figure 4B). Therefore, the presence of explicit ions in the “explicit_ions” simulation appears to have
stabilized the antibody throughout modification of its electrostatic environment.ȱŘŖŗŞǰȱŝǰȱ¡ȱȱȱ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Figure 4. RMSD analysis of the four antibody chains. The RMSD of the two heavy chains (B and D)
and light chains (A and C) for A: explicit; B: implicit; and C: explicit_ions simulations.
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As mentioned in the Materials and Methods, the implicit solvent approximation characterizes the
solvent as a uniform dielectric medium instead of having explicit water molecules with internal charge
distribution, polarity, and mobility. In practice, this means that no explicit interactions with water,
including protein stabilization by H-bonds with water molecules or OH moieties or directly with
ions, are possible. The applied ionic strength of 5 × 10−2 M homogenously modified the electrostatic
properties of the medium containing the antibody so that the ionic sources of the field are not explicitly
included. Contrary to that, in the “explicit_ions” system, all the sources of the electrostatic field
(charged antibody residues as well as solvent ions) are explicitly present in the system, while the water
is still represented as a homogenous medium. The explicit ions can now interact with the antibody in
a similar way to the fully explicit simulation and this, in light of the presented RMSD analysis, seems
to have a visible impact on maintaining the structural stability of the antibody, and this point will be
discussed further below.
The RMSF of the four chains is shown in Figure 5, and these indicate the following. Firstly,
as might be expected, amino acids within the variable domains (VH and VL) have generally fluctuated
more than in the constant domains (CL, CH1, CH2, and CH3) (Figure 5A–F). This could be attributed to
the tendency of antibodies to have flexible variable domains, which allow them to better search for and
ultimately bind their target. Wang and colleagues have noticed a similar trend using deglycosylated
IgG2a antibody in an explicit system [18]. The same authors have additionally shown slight differences
in RMSF between similar domains of the two identical heavy or light chains. Secondly, the main linker
region (CH1–CH2 linker), which connects the two Fabs into the Fc region, did not show a very high
RMSF, as was expected (Figure 5D–F). This is attributed to the fact that this CH1–CH2 linker is very
short (10 amino acids) when compared to the regions they are connecting in the Fab (227 amino acids)
and Fc (205 amino acids). Therefore, this linker would require small movement to implement large
deviation in the overall Fab or Fc alignment (thus resembling door hinges). Thirdly, the CH3 domains
of the “implicit” and “explicit_ions” simulations have fluctuated higher than the explicit simulation,
especially towards the C-terminal of the antibody (Figure 5D–F). Furthermore, the “implicit” system
video (Supplementary Video S2) demonstrates an unfolding of the C-terminal loops of the two heavy
chains (B and D), which contributes to the high RMSF values of these CH3 domains (Figure 5E).
Moreover, our previous experience that an RMSF of 5 Å for a residue in an α–helical structure is
substantial and usually means that the helix structure is strongly affected or even unfolded, while the
same value for a residue in a loop region or residue responsible for binding a ligand is modest. Thus,
visual analysis of the structures is still necessary to interpret the RMSF values.
Visual analysis of the trajectory for the “explicit_ions” (some details are visible in Supplementary
Move S3), indicates that the explicit Cl− ions interact with the Fab C-terminus. The reason for this is
apparent in Figure 2B, where we display the GB electrostatic potential on the antibody surface. The Fab
regions tend to be positive and therefore attract the negative solute ions. These in turn provide a strong,
local neutralization that is absent in the fully implicit solvent model, accounting for the stabilization
we observe. This observation suggests that the explicit treatment of ions should be considered with
the implicit water model in any protein system.
The RMSF analysis of the antibody structure indicates that the two light (A and C) and two
heavy (B and D) chains are still composed of rigid structural domains (Light: CL and VL; heavy:
VH, CH1, CH2, and CH3), as well as flexible linkers. To deconvolute the contribution of each to the
overall structural changes, we calculated RMSD separately for each of the 12 domains, as presented
in Supplementary Figures S1–S3. The CH1–CH2 linker region, the variable domains (VL and VH),
and CH3 domains have relatively high RMSD values when compared to other domains and linker
regions as shown on Supplementary Figures S1 and S2. Moreover, the RMSD values of the analyzed
domains were lower in the explicit simulation than the two implicit simulations, reflecting a common
tendency of the GB method to decrease the energy barriers and therefore speed-up conformational
sampling [24]. This comprehensive RMSD analysis has mirrored the observed unfolding of the N-
and C-terminals in the implicit simulations (Supplementary Figure S2), as additionally observed in
Antibodies 2018, 7, 21 9 of 14
the “implicit” video (Supplementary Video S2). The “explicit_ions” simulation has shown similar
unfolding of the N-terminal VL (chain A), yielding the high RMSD values of Supplementary Figure S3A
and Supplementary Video S3. However, this “explicit_ions” simulation was more stable than the
“implicit” simulation, and the high RMSD values of CH3 domains (chains D and B) as well as VL
(chains C), in Supplementary Figure S3B–D, did not reflect unfolding but an entire movement of the
Fab region towards the Fc region. We emphasize that neither the domains, the Fab/Fc regions, nor the
entire antibody unfold as indicated by the RMSD calculated for all the interesting fragments separately;
the relatively large values obtained for longer fragments reflect the internal flexibility of the antibody.
The corresponding RMSD plots are included in Supplementary Materials.
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Figure 5. RMSF analysis of the four antibody chains. RMSF values plotted for each residue for the two
light (A–C) and two heavy (D–F) chains. Each domain is depicted on the RMSF figures, separated by
dark grey regions that represent the linkers. The inset schemes indicate the analyzed fragment location
in the antibody 3D structure.
In order to better interpret the RMSD/RMSF values, it is necessary to measure the Fab/Fc
movements by monitoring the angles across the CH1–CH2 linker (Figure 6A). The angles measured
in the “implicit” simulation show movements of the right Fab towards the Fc region (reduction in
angle R) combined by an opposite movement of the left Fab away from the Fc region (increase in
angle L) (Figure 6C), and this contributed to the high RMSD values. In comparison, in the “explicit”
simulation, the two Fab regions have slightly moved towards the Fc region (Figure 6B). The angles
of the “explicit_ions” simulation have shown more general fluctuations of the Fabs (Figure 6D). It is
important to note that movements of these Fc and Fab regions were not in a completely flat plane,
and the sum of the angles is not consistently 360◦ (e.g., see Figure 6B).
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Figure 6. Movement analysis of the antibody Fabs and Fc fragments. Movements of the angles shown
in (A); These angle changes were measured through each of the three simulations as illustrated in
(B) explicit; (C) implicit; and (D) explicit_ions.
Since it is understood that the implicit solvent simulation explores the conformational space faster
than its explicit counterpart [24], it is interesting to verify this for the antibody model and determine
the acceleration factor. Visual analysis of implicit trajectories revealed that the antibody achieves
the most similar structure to the one observed after 100 ns of explicit trajectory after 16.88 ns of the
simulation, which gives a speedup factor of ~6. Therefore, the elapsed time in the “implicit” simulation
might be scaled by 6 when compared to the “explicit” time, as we have done for the RMSD plots
shown in Figure 7. Interestingly, we see that the RMSD values of the “explicit” simulation have aligned
well with the implicit models. Similar alignments were tested for the angles from Figure 5B,C; they
show a similar trend for the top and right angles and for the periodicity of the left angel (Figure 8).
Other researchers, based on the time required to achieve a particular conformation or on a defined
angle flip frequency (depending on the system studied), have indicated the range of anticipated
speedup of implicit systems from ~0.7-fold to ~60-fold for different structures, depending on the size
of the molecules and the details of the transition [24]. The GB approximation in the implicit system is
associated with poor algorithmic complexity that scales as ~n2 (n: number of solute atoms), whereas
the PME-based explicit simulations scale as ~N logN (N: total number of solvent and solute atoms
combined). Thus, even though n≪ N in a typical simulation, the nominal computational speed of
the GB model can become much lower than that of the corresponding explicit-solvent simulation for
large systems (100,000 atoms or more) [26], whereas the speed of conformational sampling in implicit
simulations can be ~2–20 times faster than explicit simulations [25,38]. Consequently, despite the
algorithmic limitation of the GB model, the speedup due to conformational sampling can enhance the
overall speedup and generate faster GB-based implicit models [24].
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In our case, we find that the explicit simulations consumed 4 times more of the computational
time (core-hours) on the ARCHIE-WeSt supercomputer than the implicit simulations. Therefore,
the observed total speedup of the explicit method is around 24.
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the implicit system through multiplying by a conversion factor of 6.
ȱŘŖŗŞǰȱŝǰȱ¡ȱȱȱȱ ȱ ŗŗȱ ȱ ŗŚȱ

ȱȱǰȱ ȱȱȱȱ¡ȱȱȱŚȱȱȱȱȱȱ
ȱǻȬǼȱȱȱ
Ȭȱȱȱȱȱǯȱǰȱȱ
ȱȱȱȱȱ¡ȱȱȱȱŘŚǯȱ ȱ
ȱ
ȱŝǯȱȱ¡ȱ ȱȱȱ¡ȱ¢ǯȱȱȱ ȱȱȱ
ȱȱ¢ȱȱ¢ȱ¢ȱȱȱȱȱŜǯȱ
ȱ
ȱŞǯȱȱ¡ȱ ȱȱȱ¡ȱ¢ǯȱȱȱ ȱȱȱ
ȱȱ¢ȱȱ¢ȱ¢ȱȱȱȱȱŜǯȱ
Śǯȱȱ
ȱȱȱ¢ȱȱȱȱȱȱȱ ȱȱ
ȱȱȱȱ¢ȱȱȱȱȱ¡¢ȱȱ¢Ȭȱ¢ǯȱ
Figure 8. Angle extrapolation between implicit and explicit systems. Time values were corrected for
the implicit system through multiplying by a conversion factor of 6.
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4. Conclusions
Comparison of the antibody behavior in three different solvent environments were conducted to
gain valuable structural analysis and to provide operational flexibility for antibody-based analysis.
All three systems have shown an overall stability when the RMSD and RMSF of different sections of
the antibody were analyzed. We estimate that the explicit system was ~6 times slower in exploring
configurational space and consumed ~4 times more computing time (core hours) on our supercomputer
when compared to implicit simulations. Therefore, the total speedup factor of the implicit solvent
method in the case of IgG is estimated to be around 24. Although the quality (in the meaning of
structural similarity to the initial conformation of the antibody) in the case of the explicit simulation
was better than the implicit simulation, this could be attributed to the fact that the explicit simulation
is only representing the first 16.88 ns of the implicit counterpart. In addition, the quality of the
implicit simulation was enhanced by explicitly adding the ions to stabilize the electrostatic search
within the system. This enhancement is evidenced by the loss of unfolding in the C-terminal loops
when compared to the implicit simulation (as shown on Supplementary Videos S1–S3). Subsequently,
the explicit_ions simulation can be used to predict the antibody behavior on the longer term and to
perform a wider scan of possible conformations. On the other hand, the explicit model can be adopted
to anticipate short-term behavior of this biomolecule with full atomistic detail.
MD simulations represent a valuable tool to analyze the dynamics of movements in response
to external factors such as solvent molecules and their targeted antigens. This allows a more
accurate estimate of various applications, such as the thermodynamics and kinetics associated
with antibody-target recognition, antibody mutation and humanization, CDRs grafting, homology
modelling, binding to intrinsically disordered proteins, and antibody allostery. There is an ongoing
argument to specify the accurate time length of these simulations to reflect the experimental
environments. We have estimated a 100 ns of simulations time to be sufficient in this case. However,
further runs of the explicit model for longer times will be always beneficial, if computational resources
are available, and can be addressed in the future to allow further inspection of the hinge region.
In addition, it will also be useful to analyze the effect of adding specific molecules at specific positions
of the binding sites (both with implicit and explicit solvents) to examine their influence on the binding
of these antibodies to their designated targets. Finally, this study can be extended to analyze other
important antibody subclasses, like IgG1, and compare their structural differences.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4468/7/3/21/s1,
Supplementary Figure S1: RMSD analysis of each chain (and component VL, CL, VH, CH1, CH2, CH3, and linker
parts) in the explicit solvent and ions simulation, Supplementary Figure S2: RMSD analysis of each chain (and
component parts) in the implicit solvent and ions simulation, Supplementary Figure S3: RMSD analysis of each
chain (and component parts) in the implicit solvent/explicit ions simulation, Supplementary Video S1: explicit
simulation, Supplementary Video S2: implicit simulation, and Supplementary Video S3: explicit_ions simulation.
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